To date, five treatments have been approved for GIST: imatinib, sunitinib, regorafenib and ripretinib for KIT-mutant GIST and avapritinib for patients with D842V-mutant GIST (Demetri et al. 2002, 2006, 2012b; Blay et al. 2020; Heinrich et al. 2020). This evidence concerns the gene KIT and gastrointestinal stromal tumor.